Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Opthea.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Clarity’s imaging agent can identify prostate cancer lesions at double the rate
News
Market Highlights: Meta surges 14pc, uranium stocks most traded by Aussies, and 5 small caps to watch today
News
In Case You Missed It: Drilling deals, niobium and a Peruvian project
Health & Biotech
ASX Health Stocks: Opthea up 13pc on $85m funding from giant investment firm Carlyle, new investor
News
Market Highlights: S&P 500 just 1pc shy of record highs, and Macquarie bullish on small caps in 2024
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: ASX ends flat, but it’s not a good flat. More an Oxford Dictionary ‘to lack vigour; dull and lifeless’ flat
Health & Biotech
Check Up: Australian biotech sector continues to be a magnet for US investors
News
Top 10 at 11: Sarytogan Graphite up 51pc after Central Kazakhstan update
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: ASX200 makes it a hat-trick after Tech Sector triumph
Health & Biotech
Move over Neuren – Bioshares reckons these ASX health stocks could pop with upcoming key catalysts
Experts
MoneyTalks: Brokers say Rumble could surge 2x on zinc demand; Opthea 4x if clinical trials succeed
Health & Biotech
ASX Health Stocks: Imricor jumps 19pc on ethics approval to commence cardiac arrest study
Health & Biotech
ASX Health Stocks: Clarity Pharma shows effectiveness in diagnosing prostate lesions in Phase 1 trial
News
Market Highlights: Defiant Wall Street, Man U for sale, and 5 ASX small caps to watch today
Health & Biotech